Compare Novo Nordisk A/S (NVO) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Xcel Energy Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Xcel Energy Inc trades at $73.78 (market cap $45.82B). The key difference: Novo Nordisk A/S is far larger — about 3.6× Xcel Energy Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Xcel Energy Inc for 61 Days on average.
| NVO | XEL | |
|---|---|---|
Market Cap | $165.31B | $45.82B |
Volume | 11,432,838 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $63.98 | $83.91 |
52-Week Low | $35.29 | $69.39 |
Typical Hold Time | 116 Days | 61 Days |
Enterprise Value | $179.56B | $84.14B |
Dividend Yield | 4.71% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Xcel Energy (XEL) trades at $73.78, up 1.87% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent earnings beats. Recent news highlights growing data center power demand and a $60B capital investment plan driving future growth. Analyst consensus remains positive with a $90.83 price target representing 23% upside potential.
XEL offers attractive total return potential through earnings growth and dividend yield, supported by regulated utility business model and infrastructure investments. Key risks include wildfire liabilities, rising interest rates impacting financing costs, and execution challenges with large capital projects. The stock presents a balanced opportunity for income and growth investors seeking utility exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
